Nigeria’s health authorities say they have recorded no additional confirmed cases of Bundibugyo Ebola disease since an imported infection was identified in Abuja, while 28 people linked to the patient remain under monitoring.
In an update issued on 10 November, the Nigeria Centre for Disease Control and Prevention said the country had confirmed one imported case as of 9 November. Of 62 people identified as contacts, 34 had completed their individual 21-day follow-up, and 28 were still being monitored.
The figures mark progress in the response that began after the case was confirmed on 20 October. They do not mean that all monitoring has finished or that a person identified as a contact has Ebola. The agency says follow-up helps health teams detect symptoms early and arrange an appropriate response.
Why the monitoring periods differ
By the time the agency issued its update, three weeks had passed since the case was confirmed. That is not the same as saying every contact had completed 21 days of follow-up. Each person’s monitoring period is assessed individually, and the agency cautioned against treating the date of the original confirmation as a shared end date for everyone.
The latest figures show how the position has changed. An earlier NCDC dashboard snapshot, based on information as of 7 November, recorded 17 contacts who had exited follow-up and 45 still being followed. The later update reported that another 17 had completed the period, leaving 28 under monitoring.
Continued surveillance and investigation of alerts remain part of the response.
The imported case and the response
The patient had travelled to Nigeria from Uganda and developed symptoms after arriving. The infection was confirmed in the Federal Capital Territory on 20 October. The patient was medically evacuated to Switzerland on 26 October for further care. Public health investigators have been examining the travel and exposure history to establish the likely source of infection; the travel route alone does not establish where the infection occurred.
Nigeria’s response has involved contact tracing, laboratory testing and investigation of reported alerts, as well as infection prevention and surveillance at points of entry. Federal and state authorities and health partners have been involved in the work. The agency has asked public and private healthcare workers to consider travel and possible exposure histories, use infection prevention measures and report suspected cases promptly.
Someone who develops symptoms after a possible exposure has been advised to avoid contact with others and call the NCDC’s toll-free number, 6232, for guidance before travelling to a health facility. Symptoms alone do not confirm Ebola; assessment and laboratory testing are needed to distinguish it from other illnesses.
The wider outbreak
Bundibugyo virus can cause a severe form of Ebola disease. It spreads through direct contact with the blood or other body fluids of an infected person, or with contaminated materials. People are not considered infectious before symptoms begin. Early symptoms can include fever, tiredness, muscle pain, headache and a sore throat, which can also occur with other infections.
The period between infection and symptoms can range from two to 21 days. There is currently no approved vaccine or specific treatment for Bundibugyo virus disease. Supportive medical care, including fluids and treatment of symptoms, remains important, while vaccine candidates are being studied.
The Nigerian case sits within a wider regional response to an outbreak first declared in the Democratic Republic of the Congo in May. As of 10 November, the Congolese total stood at 10,990 confirmed cases, including 5,354 deaths, using information through 8 November. Kenya had reported nine confirmed cases, including two deaths, as of 9 November.
Those figures describe different national situations and reporting dates. In Nigeria, the immediate milestone is that more than half of the identified contacts had completed their individual monitoring periods, while the country’s reported confirmed case count remained at one. Health teams must still follow the remaining contacts and assess new alerts as they arise.
